Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases

Miles, Timothy J., Hennessy, Alan J., Bax, Ben ORCID: https://orcid.org/0000-0003-1940-3785, Brooks, Gerald, Brown, Barry S., Brown, Pamela, Cailleau, Nathalie, Chen, Dongzhao, Dabbs, Steven, Davies, David T., Esken, Joel M., Giordano, Ilaria, Hoover, Jennifer L., Huang, Jianzhong, Jones, Graham E., Kusalakumari Sukmar, Senthill K., Spitzfaden, Claus, Markwell, Roger E., Minthorn, Elisabeth A., Rittenhouse, Steve, Gwynn, Michael N. and Pearson, Neil D. 2013. Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases. Bioorganic and Medicinal Chemistry Letters 23 (19) , pp. 5437-5441. 10.1016/j.bmcl.2013.07.013

Full text not available from this repository.

Abstract

During the course of our research to find novel mode of action antibacterials, we discovered a series of hydroxyl tricyclic compounds that showed good potency against Gram-positive and Gram-negative pathogens. These compounds inhibit bacterial type IIA topoisomerases. Herein we will discuss structure–activity relationships in this series and report advanced studies on compound 1 (GSK966587) which demonstrates good PK and in vivo efficacy properties. X-ray crystallographic studies were used to provide insight into the structural basis for the difference in antibacterial potency between enantiomers.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Publisher:	Elsevier
ISSN:	0960-894X
Date of Acceptance:	9 July 2013
Last Modified:	23 Oct 2022 14:03
URI:	https://orca.cardiff.ac.uk/id/eprint/112626

Citation Data

Cited 56 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item